Over the past decade, our understanding of the pathology of epilepsy and the causes of drug resistance has grown substantially, providing opportunities for the development of more effective anti-epileptic drugs (AEDs). Here, Löscher and colleagues discuss issues that may have hampered previous AED discovery and propose strategies for the development of improved epilepsy therapies that offer a compelling case for industry investment.
- Wolfgang Löscher
- Henrik Klitgaard
- Dieter Schmidt
